CN114053410A - 一种治疗冠状病毒感染及其相关症状的大蒜素制剂 - Google Patents
一种治疗冠状病毒感染及其相关症状的大蒜素制剂 Download PDFInfo
- Publication number
- CN114053410A CN114053410A CN202111406430.XA CN202111406430A CN114053410A CN 114053410 A CN114053410 A CN 114053410A CN 202111406430 A CN202111406430 A CN 202111406430A CN 114053410 A CN114053410 A CN 114053410A
- Authority
- CN
- China
- Prior art keywords
- stirring
- allicin
- solution
- standing
- formula proportion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 title claims abstract description 38
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 235000010081 allicin Nutrition 0.000 title claims abstract description 38
- 208000001528 Coronaviridae Infections Diseases 0.000 title claims abstract description 30
- 208000024891 symptom Diseases 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims abstract description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000003862 glucocorticoid Substances 0.000 claims abstract description 20
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims abstract description 19
- 108010036949 Cyclosporine Proteins 0.000 claims abstract description 19
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 19
- 102000014150 Interferons Human genes 0.000 claims abstract description 19
- 108010050904 Interferons Proteins 0.000 claims abstract description 19
- 229960001265 ciclosporin Drugs 0.000 claims abstract description 19
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 19
- 229940079322 interferon Drugs 0.000 claims abstract description 19
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229960001800 nefazodone Drugs 0.000 claims abstract description 19
- 239000000843 powder Substances 0.000 claims abstract description 19
- 239000006041 probiotic Substances 0.000 claims abstract description 19
- 230000000529 probiotic effect Effects 0.000 claims abstract description 19
- 235000018291 probiotics Nutrition 0.000 claims abstract description 19
- 229960000278 theophylline Drugs 0.000 claims abstract description 19
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000010282 Emodin Substances 0.000 claims abstract description 17
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 claims abstract description 17
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 claims abstract description 17
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 claims abstract description 17
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 claims abstract description 17
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 claims abstract description 17
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000003381 stabilizer Substances 0.000 claims abstract description 11
- 239000004094 surface-active agent Substances 0.000 claims abstract description 10
- 229930105110 Cyclosporin A Natural products 0.000 claims abstract description 7
- 239000003443 antiviral agent Substances 0.000 claims abstract description 7
- 229930182912 cyclosporin Natural products 0.000 claims abstract description 7
- 239000003112 inhibitor Substances 0.000 claims abstract description 7
- 238000003756 stirring Methods 0.000 claims description 90
- 239000000243 solution Substances 0.000 claims description 42
- -1 polyoxyethylene Polymers 0.000 claims description 36
- 238000010438 heat treatment Methods 0.000 claims description 30
- 238000005303 weighing Methods 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 21
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 19
- 235000010445 lecithin Nutrition 0.000 claims description 19
- 229940067606 lecithin Drugs 0.000 claims description 19
- 239000000787 lecithin Substances 0.000 claims description 19
- AEUAEICGCMSYCQ-UHFFFAOYSA-N 4-n-(7-chloroquinolin-1-ium-4-yl)-1-n,1-n-diethylpentane-1,4-diamine;dihydrogen phosphate Chemical group OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 AEUAEICGCMSYCQ-UHFFFAOYSA-N 0.000 claims description 18
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 18
- 229960002328 chloroquine phosphate Drugs 0.000 claims description 18
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 18
- OMZHXQXQJGCSKN-UHFFFAOYSA-N ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)-1h-indol-1-ium-3-carboxylate;chloride Chemical compound Cl.CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 OMZHXQXQJGCSKN-UHFFFAOYSA-N 0.000 claims description 18
- 239000000194 fatty acid Substances 0.000 claims description 18
- 229930195729 fatty acid Natural products 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 7
- 239000011259 mixed solution Substances 0.000 claims description 6
- 239000004166 Lanolin Substances 0.000 claims description 4
- 229940039717 lanolin Drugs 0.000 claims description 4
- 235000019388 lanolin Nutrition 0.000 claims description 4
- 241000220479 Acacia Species 0.000 claims description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 3
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 claims description 3
- 229960000329 ribavirin Drugs 0.000 claims description 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 3
- 229940093257 valacyclovir Drugs 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims 6
- 230000000694 effects Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 3
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种治疗冠状病毒感染及其相关症状的大蒜素制剂,各组分按其质量百分比计为:大蒜素:1%‑40%、大黄素:1%‑35%、水:1%‑30%、乙醇:1%‑10%、抑制剂:1%‑10%、干扰素:1%‑6%、抗病毒剂:1%‑5%、免疫球蛋白:0.5%‑3%、调节剂:1%‑3%、茶碱:1%‑2.5%、环孢素:1%‑2%、奈法唑酮:1%‑2%、益生菌粉:1%‑2%、稳定剂:1%‑2%、表面活性剂:1%‑2%,本发明的有益效果是:通过加入了大蒜素、大黄素,实现了大蒜素、大黄素进行混合,并共同治疗冠状病毒感染及其相关症状,对治疗效果进行提升,通过加入了调节剂,调节剂为糖皮质激素,实现了对药剂的抗炎作用进行提升处理。
Description
技术领域
本发明涉及大蒜素制剂技术领域,具体为一种治疗冠状病毒感染及其相关症状的大蒜素制剂。
背景技术
在过去的几十年中,由冠状病毒引起的疾病对全球公共卫生造成了巨大威胁,如急性呼吸综合症病毒(SARS)、中东呼吸综合症病毒(MERS)以及 19 年出现的新型冠状病毒(2019-nCoV)等,冠状病毒感染引发的肺部疾病往往紧随着不同程度的并发症,尤其是老年患者以及有慢性基础疾病者预后较差,周期较长,且存在个体差异;
大蒜素作为一种临床应用多年的药物,具有药理作用广泛、疗效确切且安全无副作用的特点,目前治疗冠状病毒感染及其相关症状的制剂副作用较大且价格昂贵,对治疗冠状病毒感染及其相关症状的效果不佳,对治疗冠状病毒感染及其相关症状带来了很大的困难。
发明内容
本发明的目的在于提供一种治疗冠状病毒感染及其相关症状的大蒜素制剂,以解决上述背景技术中提出的问题。
为实现上述目的,本发明提供如下技术方案一种治疗冠状病毒感染及其相关症状的大蒜素制剂,各组分按其质量百分比计为:大蒜素:1%-40%、大黄素:1%-35%、水:1%-30%、乙醇:1%-10%、抑制剂:1%-10%、干扰素:1%-6%、抗病毒剂:1%-5%、免疫球蛋白:0.5%-3%、调节剂:1%-3%、茶碱:1%-2.5%、环孢素:1%-2%、奈法唑酮:1%-2%、益生菌粉:1%-2%、稳定剂:1%-2%、表面活性剂:1%-2%。
作为优选,所述抑制剂为磷酸氯喹。
作为优选,所述抗病毒剂为盐酸阿比多尔、利巴韦林、伐昔洛韦其中的一种或几种混合物。
作为优选,所述调节剂为糖皮质激素。
作为优选,所述稳定剂为卵磷脂、羊毛脂、阿拉伯胶其中的一种。
作为优选,所述表面活性剂为聚氧乙烯脂肪酸酯。
作为优选,所述稳定剂与表面活性剂的比例为1:1。
一种治疗冠状病毒感染及其相关症状的大蒜素制剂的制备方法,包括以下步骤:
S1、配置溶液一:按照配方比例,称取磷酸氯喹、盐酸阿比多尔,将磷酸氯喹加入配方比例的乙醇内,置于容器内进行搅拌处理,搅拌时间为2-10min,搅拌完成后,继续向容器内加入盐酸阿比多尔,继续搅拌,搅拌时间为5-20min,搅拌均匀后静置10-60min;
S2、配置溶液二:按照配方比例,再称取免疫球蛋白、糖皮质激素、卵磷脂,将免疫球蛋白、糖皮质激素、卵磷脂加入配方比例的水内,置于容器内进行搅拌处理,搅拌时间为1-4min,搅拌均匀后静置4-20min;
S3、混合溶液:按照配方比例,再称取干扰素、益生菌粉、聚氧乙烯脂肪酸酯,将溶液一加入溶液二内,再加入干扰素、益生菌粉、聚氧乙烯脂肪酸酯进行加热搅拌,搅拌时间为20-80min,加热温度为20-35℃,搅拌均匀后静置50-140min;
S4、溶液混合:按照配方比例,再称取茶碱、环孢素、奈法唑酮,将环孢素、奈法唑酮加入S3得到的溶液内,加入后进行加热搅拌处理,搅拌时间为10-40min,加热温度为30-50℃,搅拌均匀后静置10-40min,继续加入茶碱,常温下搅拌10-25min,搅拌后静置5-20min;
S5、混合搅拌:按照配方比例,将大蒜素、大黄素加入步骤S3得到的溶液内,进行加热搅拌,搅拌时间为10-50min,加热温度为20-30℃,静置40-90min,即可得到制剂。
与现有技术相比,本发明的有益效果是:通过加入了大蒜素、大黄素,实现了大蒜素、大黄素进行混合,并共同治疗冠状病毒感染及其相关症状,对治疗效果进行提升,通过加入了调节剂,调节剂为糖皮质激素,实现了对药剂的抗炎作用进行提升处理,通过加入了稳定剂,稳定剂为卵磷脂、羊毛脂、阿拉伯胶其中的一种,实现了对制剂内的辅助治疗作用。
具体实施方式
本发明提供一种技术方案:一种治疗冠状病毒感染及其相关症状的大蒜素制剂,各组分按其质量百分比计为:大蒜素:1%-40%、大黄素:1%-35%、水:1%-30%、乙醇:1%-10%、抑制剂:1%-10%、干扰素:1%-6%、抗病毒剂:1%-5%、免疫球蛋白:0.5%-3%、调节剂:1%-3%、茶碱:1%-2.5%、环孢素:1%-2%、奈法唑酮:1%-2%、益生菌粉:1%-2%、稳定剂:1%-2%、表面活性剂:1%-2%。
其中,所述抑制剂为磷酸氯喹。
其中,所述抗病毒剂为盐酸阿比多尔、利巴韦林、伐昔洛韦其中的一种或几种混合物。
其中,所述调节剂为糖皮质激素。
其中,所述稳定剂为卵磷脂、羊毛脂、阿拉伯胶其中的一种。
其中,所述表面活性剂为聚氧乙烯脂肪酸酯。
其中,所述稳定剂与表面活性剂的比例为1:1。
一种治疗冠状病毒感染及其相关症状的大蒜素制剂的制备方法,包括以下步骤:
S1、配置溶液一:按照配方比例,称取磷酸氯喹、盐酸阿比多尔,将磷酸氯喹加入配方比例的乙醇内,置于容器内进行搅拌处理,搅拌时间为2-10min,搅拌完成后,继续向容器内加入盐酸阿比多尔,继续搅拌,搅拌时间为5-20min,搅拌均匀后静置10-60min;
S2、配置溶液二:按照配方比例,再称取免疫球蛋白、糖皮质激素、卵磷脂,将免疫球蛋白、糖皮质激素、卵磷脂加入配方比例的水内,置于容器内进行搅拌处理,搅拌时间为1-4min,搅拌均匀后静置4-20min;
S3、混合溶液:按照配方比例,再称取干扰素、益生菌粉、聚氧乙烯脂肪酸酯,将溶液一加入溶液二内,再加入干扰素、益生菌粉、聚氧乙烯脂肪酸酯进行加热搅拌,搅拌时间为20-80min,加热温度为20-35℃,搅拌均匀后静置50-140min;
S4、溶液混合:按照配方比例,再称取茶碱、环孢素、奈法唑酮,将环孢素、奈法唑酮加入S3得到的溶液内,加入后进行加热搅拌处理,搅拌时间为10-40min,加热温度为30-50℃,搅拌均匀后静置10-40min,继续加入茶碱,常温下搅拌10-25min,搅拌后静置5-20min;
S5、混合搅拌:按照配方比例,将大蒜素、大黄素加入步骤S3得到的溶液内,进行加热搅拌,搅拌时间为10-50min,加热温度为20-30℃,静置40-90min,即可得到制剂。
实施例1、一种治疗冠状病毒感染及其相关症状的大蒜素制剂,各组分按其质量百分比计为:大蒜素:40%、大黄素:27%、水:5%、乙醇:4%、磷酸氯喹:6%、干扰素:2%、盐酸阿比多:2%、免疫球蛋白:2%、糖皮质激素:1.5%、茶碱:2.5%、环孢素:2%、奈法唑酮:1%、益生菌粉:1%、卵磷脂:2%、聚氧乙烯脂肪酸酯:2%。
一种治疗冠状病毒感染及其相关症状的大蒜素制剂的制备方法,包括以下步骤:
S1、配置溶液一:按照配方比例,称取磷酸氯喹、盐酸阿比多尔,将磷酸氯喹加入配方比例的乙醇内,置于容器内进行搅拌处理,搅拌时间为10min,搅拌完成后,继续向容器内加入盐酸阿比多尔,继续搅拌,搅拌时间为20min,搅拌均匀后静置60min;
S2、配置溶液二:按照配方比例,再称取免疫球蛋白、糖皮质激素、卵磷脂,将免疫球蛋白、糖皮质激素、卵磷脂加入配方比例的水内,置于容器内进行搅拌处理,搅拌时间为4min,搅拌均匀后静置20min;
S3、混合溶液:按照配方比例,再称取干扰素、益生菌粉、聚氧乙烯脂肪酸酯,将溶液一加入溶液二内,再加入干扰素、益生菌粉、聚氧乙烯脂肪酸酯进行加热搅拌,搅拌时间为80min,加热温度为35℃,搅拌均匀后静置140min;
S4、溶液混合:按照配方比例,再称取茶碱、环孢素、奈法唑酮,将环孢素、奈法唑酮加入S3得到的溶液内,加入后进行加热搅拌处理,搅拌时间为40min,加热温度为50℃,搅拌均匀后静置40min,继续加入茶碱,常温下搅拌25min,搅拌后静置20min;
S5、混合搅拌:按照配方比例,将大蒜素、大黄素加入步骤S3得到的溶液内,进行加热搅拌,搅拌时间为50min,加热温度为30℃,静置90min,即可得到制剂。
实施例2、一种治疗冠状病毒感染及其相关症状的大蒜素制剂,各组分按其质量百分比计为:大蒜素:15%、大黄素:20%、水:17%、乙醇:10%、磷酸氯喹:10%、干扰素:6%、盐酸阿比多:5%、免疫球蛋白:2.5%、糖皮质激素:3%、茶碱:2.5%、环孢素:2%、奈法唑酮:2%、益生菌粉:1%、卵磷脂:2%、聚氧乙烯脂肪酸酯:2%。
一种治疗冠状病毒感染及其相关症状的大蒜素制剂的制备方法,包括以下步骤:
S1、配置溶液一:按照配方比例,称取磷酸氯喹、盐酸阿比多尔,将磷酸氯喹加入配方比例的乙醇内,置于容器内进行搅拌处理,搅拌时间为2min,搅拌完成后,继续向容器内加入盐酸阿比多尔,继续搅拌,搅拌时间为5min,搅拌均匀后静置10min;
S2、配置溶液二:按照配方比例,再称取免疫球蛋白、糖皮质激素、卵磷脂,将免疫球蛋白、糖皮质激素、卵磷脂加入配方比例的水内,置于容器内进行搅拌处理,搅拌时间为1min,搅拌均匀后静置4min;
S3、混合溶液:按照配方比例,再称取干扰素、益生菌粉、聚氧乙烯脂肪酸酯,将溶液一加入溶液二内,再加入干扰素、益生菌粉、聚氧乙烯脂肪酸酯进行加热搅拌,搅拌时间为20min,加热温度为20℃,搅拌均匀后静置50min;
S4、溶液混合:按照配方比例,再称取茶碱、环孢素、奈法唑酮,将环孢素、奈法唑酮加入S3得到的溶液内,加入后进行加热搅拌处理,搅拌时间为10min,加热温度为30℃,搅拌均匀后静置10min,继续加入茶碱,常温下搅拌10min,搅拌后静置5min;
S5、混合搅拌:按照配方比例,将大蒜素、大黄素加入步骤S3得到的溶液内,进行加热搅拌,搅拌时间为10min,加热温度为20℃,静置40min,即可得到制剂。
实施例3、一种治疗冠状病毒感染及其相关症状的大蒜素制剂,各组分按其质量百分比计为:大蒜素:25%、大黄素:20%、水:20%、乙醇:5%、磷酸氯喹:8%、干扰素:4%、盐酸阿比多:3%、免疫球蛋白:2%、糖皮质激素:3%、茶碱:2%、环孢素:2%、奈法唑酮:1%、益生菌粉:1%、卵磷脂:2%、聚氧乙烯脂肪酸酯:2%。
一种治疗冠状病毒感染及其相关症状的大蒜素制剂的制备方法,包括以下步骤:
S1、配置溶液一:按照配方比例,称取磷酸氯喹、盐酸阿比多尔,将磷酸氯喹加入配方比例的乙醇内,置于容器内进行搅拌处理,搅拌时间为5min,搅拌完成后,继续向容器内加入盐酸阿比多尔,继续搅拌,搅拌时间为15min,搅拌均匀后静置30min;
S2、配置溶液二:按照配方比例,再称取免疫球蛋白、糖皮质激素、卵磷脂,将免疫球蛋白、糖皮质激素、卵磷脂加入配方比例的水内,置于容器内进行搅拌处理,搅拌时间为2min,搅拌均匀后静置10min;
S3、混合溶液:按照配方比例,再称取干扰素、益生菌粉、聚氧乙烯脂肪酸酯,将溶液一加入溶液二内,再加入干扰素、益生菌粉、聚氧乙烯脂肪酸酯进行加热搅拌,搅拌时间为55min,加热温度为30℃,搅拌均匀后静置90min;
S4、溶液混合:按照配方比例,再称取茶碱、环孢素、奈法唑酮,将环孢素、奈法唑酮加入S3得到的溶液内,加入后进行加热搅拌处理,搅拌时间为25min,加热温度为40℃,搅拌均匀后静置25min,继续加入茶碱,常温下搅拌20min,搅拌后静置10min;
S5、混合搅拌:按照配方比例,将大蒜素、大黄素加入步骤S3得到的溶液内,进行加热搅拌,搅拌时间为30min,加热温度为25℃,静置65min,即可得到制剂。
在本发明中,除非另有明确的规定和限定,术语“安装”、“设置”、“连接”、“固定”、“旋接”等术语应做广义理解,例如,可以是固定连接,也可以是可拆卸连接,或成一体;可以是机械连接,也可以是电连接;可以是直接相连,也可以通过中间媒介间接相连,可以是两个元件内部的连通或两个元件的相互作用关系,除非另有明确的限定,对于本领域的普通技术人员而言,可以根据具体情况理解上述术语在本发明中的具体含义。
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。
Claims (8)
1.一种治疗冠状病毒感染及其相关症状的大蒜素制剂,其特征在于,各组分按其质量百分比计为:大蒜素:1%-40%、大黄素:1%-35%、水:1%-30%、乙醇:1%-10%、抑制剂:1%-10%、干扰素:1%-6%、抗病毒剂:1%-5%、免疫球蛋白:0.5%-3%、调节剂:1%-3%、茶碱:1%-2.5%、环孢素:1%-2%、奈法唑酮:1%-2%、益生菌粉:1%-2%、稳定剂:1%-2%、表面活性剂:1%-2%。
2.根据权利要求1所述的一种治疗冠状病毒感染及其相关症状的大蒜素制剂,其特征在于:所述抑制剂为磷酸氯喹。
3.根据权利要求1所述的一种治疗冠状病毒感染及其相关症状的大蒜素制剂,其特征在于:所述抗病毒剂为盐酸阿比多尔、利巴韦林、伐昔洛韦其中的一种或几种混合物。
4.根据权利要求1所述的一种治疗冠状病毒感染及其相关症状的大蒜素制剂,其特征在于:所述调节剂为糖皮质激素。
5.根据权利要求1所述的一种治疗冠状病毒感染及其相关症状的大蒜素制剂,其特征在于:所述稳定剂为卵磷脂、羊毛脂、阿拉伯胶其中的一种。
6.根据权利要求1所述的一种治疗冠状病毒感染及其相关症状的大蒜素制剂,其特征在于:所述表面活性剂为聚氧乙烯脂肪酸酯。
7.根据权利要求1所述的一种治疗冠状病毒感染及其相关症状的大蒜素制剂,其特征在于:所述稳定剂与表面活性剂的比例为1:1。
8.一种治疗冠状病毒感染及其相关症状的大蒜素制剂的制备方法,其特征在于:包括以下步骤:
S1、配置溶液一:按照配方比例,称取磷酸氯喹、盐酸阿比多尔,将磷酸氯喹加入配方比例的乙醇内,置于容器内进行搅拌处理,搅拌时间为2-10min,搅拌完成后,继续向容器内加入盐酸阿比多尔,继续搅拌,搅拌时间为5-20min,搅拌均匀后静置10-60min;
S2、配置溶液二:按照配方比例,再称取免疫球蛋白、糖皮质激素、卵磷脂,将免疫球蛋白、糖皮质激素、卵磷脂加入配方比例的水内,置于容器内进行搅拌处理,搅拌时间为1-4min,搅拌均匀后静置4-20min;
S3、混合溶液:按照配方比例,再称取干扰素、益生菌粉、聚氧乙烯脂肪酸酯,将溶液一加入溶液二内,再加入干扰素、益生菌粉、聚氧乙烯脂肪酸酯进行加热搅拌,搅拌时间为20-80min,加热温度为20-35℃,搅拌均匀后静置50-140min;
S4、溶液混合:按照配方比例,再称取茶碱、环孢素、奈法唑酮,将环孢素、奈法唑酮加入S3得到的溶液内,加入后进行加热搅拌处理,搅拌时间为10-40min,加热温度为30-50℃,搅拌均匀后静置10-40min,继续加入茶碱,常温下搅拌10-25min,搅拌后静置5-20min;
S5、混合搅拌:按照配方比例,将大蒜素、大黄素加入步骤S3得到的溶液内,进行加热搅拌,搅拌时间为10-50min,加热温度为20-30℃,静置40-90min,即可得到制剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111406430.XA CN114053410A (zh) | 2021-11-24 | 2021-11-24 | 一种治疗冠状病毒感染及其相关症状的大蒜素制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111406430.XA CN114053410A (zh) | 2021-11-24 | 2021-11-24 | 一种治疗冠状病毒感染及其相关症状的大蒜素制剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114053410A true CN114053410A (zh) | 2022-02-18 |
Family
ID=80275811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111406430.XA Pending CN114053410A (zh) | 2021-11-24 | 2021-11-24 | 一种治疗冠状病毒感染及其相关症状的大蒜素制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114053410A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115252590A (zh) * | 2022-06-14 | 2022-11-01 | 苏彦雷 | 单体化合物大黄素在抗新型冠状病毒中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102844047A (zh) * | 2009-09-02 | 2012-12-26 | 诺华有限公司 | 含tlr活性调节剂的免疫原性组合物 |
CN111920786A (zh) * | 2020-08-25 | 2020-11-13 | 复旦大学附属金山医院 | 气雾状大蒜辣素在防治新冠病毒感染及其他呼吸道感染性疾病的应用 |
-
2021
- 2021-11-24 CN CN202111406430.XA patent/CN114053410A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102844047A (zh) * | 2009-09-02 | 2012-12-26 | 诺华有限公司 | 含tlr活性调节剂的免疫原性组合物 |
CN111920786A (zh) * | 2020-08-25 | 2020-11-13 | 复旦大学附属金山医院 | 气雾状大蒜辣素在防治新冠病毒感染及其他呼吸道感染性疾病的应用 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115252590A (zh) * | 2022-06-14 | 2022-11-01 | 苏彦雷 | 单体化合物大黄素在抗新型冠状病毒中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007203159B2 (en) | Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone | |
CN114053410A (zh) | 一种治疗冠状病毒感染及其相关症状的大蒜素制剂 | |
US20070021326A1 (en) | Composition and its Therapeutic Use | |
EP1556023B1 (en) | Nutritional or therapeutic compositions | |
AU2003273967A8 (en) | Use of indoleacetic acid derivatives which increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various diseases | |
JPH0137398B2 (zh) | ||
WO2023088073A1 (zh) | 一种多功能西洋参水解肽及其制备方法和应用 | |
EP2025341A1 (en) | Ointment for combating and treating skin diseases, and process for preparing said ointment | |
CS248712B2 (en) | Production method of 6 alfa-methylcorticoids | |
CN100512878C (zh) | 治疗人面部螨性皮炎药物及其制备方法 | |
CN113750041A (zh) | 一种地塞米松磷酸钠液体制剂及其制备方法 | |
CN112386653A (zh) | 一种解热退烧的大蒜素制剂及制备方法 | |
CN114028442B (zh) | 乳苣在制备用于抑制特异性皮炎的药物中的应用 | |
Jovlikizi et al. | INFLUENCE OF LUTEOLIN ON BODY AND ORGANS WEIGHT OF THE POLYCYSTIC OVARY SYNDROME (PCOS) MICE | |
CN114767769A (zh) | 一种治疗疔毒皮肤病的中药组合物及其制作方法 | |
MD1541Y (ro) | Metodă de tratament al infecţiei cu virusul SARS-CoV-2 de formă medie | |
SU1532048A1 (ru) | Способ лечени хронического обструктивного бронхита у мужчин | |
CN117815238A (zh) | 一种治疗银屑病的外用制剂及其制备方法 | |
TR2022007389A2 (tr) | Topi̇kal formülasyonlar | |
JPH0769909A (ja) | ビワの葉抽出軟膏製剤の製造方法およびそれにより得られたビワの葉抽出軟膏製剤 | |
Shulman | A Possible Mode of Action of 2: 4-Diamino-5-phenyl-thiazole Hydrochloride (Daptazole or Amiphenazole) | |
CN114712382A (zh) | 一种由几种中西药物结合组成的皮肤病药品 | |
EP0734726A2 (en) | Composition containing mercury ammonium chloride, resorcinol and sulphur | |
CN112402471A (zh) | 一种积雪草总酸的制备方法及其制备的积雪草总酸和应用 | |
CN114615997A (zh) | 包含大麻素的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220218 |
|
RJ01 | Rejection of invention patent application after publication |